Identifying Blood-Based Markers for Optimized Bipolar Androgen Therapy in mCRPC

madman

Super Moderator
1718516599705.webp


To view this content we will need your consent to set third party cookies.
For more detailed information, see our cookies page.

Samuel Denmeade, MD, of Johns Hopkins University School of Medicine, highlights his research on blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.

This research was presented as a late-breaking abstract at the 2024 American Society of Clinical Oncology Annual Meeting.
 

Online statistics

Members online
3
Guests online
422
Total visitors
425

Latest posts

Back
Top